Decoding IBD: How Accurate Are Diagnoses Across Borders?
"A look into a new study that questions how well inflammatory bowel disease is diagnosed in China compared to the US."
Inflammatory Bowel Disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is becoming more common in Asia, especially in China. While IBD is well-studied, the risk of colorectal cancer (CAC) in Asian patients with UC is similar to that of Western patients. This means that preventing CAC through colonoscopic surveillance is increasingly important in Asia.
The challenge? Most pathology in China is done in general practice, not by specialists. Since identifying dysplasia (irregular cell changes) is key for managing IBD, ensuring accurate diagnosis is crucial. This is where a new study comes in, aiming to evaluate how well pathologists in China diagnose IBD-related issues compared to gastrointestinal (GI) experts in the United States.
Telepathology, which involves remote diagnosis using digital images, offers a unique way to compare diagnostic accuracy across different regions. This approach helps to ensure that patients receive appropriate care, regardless of where they live. The study leverages this technology to assess and improve the diagnostic process in IBD.
How IBD Is Diagnosed
IBD diagnosis typically combines medical history, physical examination, endoscopic and pathological evaluations, computed tomography, magnetic resonance imaging, and increasingly routine sonographic imaging. Laboratory, serological, and stool tests can provide additional diagnostic clues in outpatient settings. Diagnosis remains challenging, particularly when distinguishing Crohn’s disease from ulcerative colitis, and clinical confidence may vary from a provisional to a confirmed diagnosis.
From UC to Modern IBD
Ulcerative colitis was the first IBD subtype to be characterized as a distinct entity, so the early history of IBD largely traces the history of UC. Historical work between the 19th and 20th centuries focused on defining diagnostic criteria and differentiating IBD from intestinal tuberculosis. The history of IBD nevertheless reflects two conditions whose pathophysiology remains incompletely understood: UC and Crohn’s disease.
Is There a Diagnostic Gap in IBD Across Continents?
The study included eight GI pathologists from the US and four pathologists from China, all experienced in GI pathology. They examined 50 colon biopsies from Chinese patients with a history of IBD. These samples, taken from eight different medical centers in China between 1999 and 2016, were digitized using an Aperio system.
- Substantial Agreement in China: The four Chinese pathologists showed significant agreement in their diagnoses, with a kappa value of 0.68.
- Agreement with US Consensus: The agreement between the Chinese pathologists and the consensus diagnosis from the US experts ranged from 0.75 to 0.80.
- Diagnostic Categories: The consensus diagnoses included negative (22 cases), LGD (22 cases), HGD (3 cases), carcinoma (2 cases), and indefinite for dysplasia (1 case).
New Evidence in Dysplasia Assessment
Recent research is examining how dysplasia is identified in patients with long-standing IBD. A case-cohort study included patients with IBD, with or without colorectal cancer, who underwent at least two surveillance endoscopic procedures at one institution between January 1, 2007, and May 31, 2023. Another study assessed diagnostic concordance by asking eight pathologists to evaluate 125 endoscopic biopsy samples containing nondysplastic and dysplastic lesions. Telepathological research has also analyzed diagnoses from 486 pediatric specimens, while one cited study involved four Chinese pathologists examining 50 digitized IBD colonic biopsies using the Aperio system from Leica Biosystems.
Where Diagnosis and Care Fall Short
Interobserver agreement in diagnosing IBD-associated neoplasia has been examined by comparing pathologists in China with subspecialized American gastrointestinal pathologists. The source notes that randomized trials demonstrating the effectiveness of surveillance programs in reducing IBD-associated mortality are lacking, although retrospective case series have reported surveillance benefits. More broadly, IBD mechanisms remain unclear and current treatments have significant limitations. Real-world practice may also reveal problems that are not fully captured by controlled trials and epidemiologic studies.
Why This Matters for IBD Patients
This study highlights the potential of telepathology to standardize and improve diagnostic accuracy in IBD, regardless of geographical location. By leveraging digital imaging and remote consultation, healthcare professionals can ensure that patients receive the most accurate diagnoses and appropriate treatment plans. This is particularly important in regions where specialized expertise may not be readily available.
Putting Patients at the Center
Patient-led research describes wellbeing for people living with IBD as complex and multidimensional. Crohn’s disease and ulcerative colitis can cause considerable morbidity, substantially diminish quality of life, and create direct and indirect economic costs for health systems. The IBD GAPPS project used separate online surveys for patients and physicians in Canada, France, Germany, Italy, Spain, the United Kingdom, and the United States. Patient expectations of care also emphasize the importance of the relationship between patients and their gastroenterologists.
Global Priorities for IBD Care
A 2025 global consensus statement brought together a multidisciplinary group of experts to identify key priorities for the future of IBD. The field has progressed from advances in understanding IBD pathophysiology to biologics, small molecules, and more personalized treatment strategies. As the field approaches the 100th anniversary of the description of Crohn’s disease, these developments frame the next phase of IBD care. Nature Reviews Gastroenterology also identifies the exposome and environmental factors as an important framework for primary and primordial prevention.
Digital Support in Practice
The COMPASS-IBD real-world longitudinal case study integrated digital mental-health screening and cognitive behavioral therapy-based digital therapy into an IBD service. Its plain-language summary reports that the approach was feasible and reduced psychological distress. The pathway could increase psychological support with minimal additional resources. Separately, a global real-world evidence study supported by AbbVie collected data from about 2,200 IBD patients across 10 countries and 103 sites to identify gaps in care and emphasize innovation.